Results 11 to 20 of about 3,018 (199)

Prognostic implications of HER2NEU‐low in metastatic breast cancer

Cancer Medicine
AbstractIntroductionWe explored characteristics and clinical outcomes of HER2‐negative and HER2‐low metastatic breast cancers using real‐world data.MethodsWe queried the National Cancer Database to identify MBC patients that were HER2‐low or HER2‐negative per immunohistochemical staining.
Zachary Neubauer, Shaakir Hasan, Robert H. Press, Arpit M. Chhabra, Jana Fox, Richard Bakst, Charles B. Simone, J. Isabelle Choi   +7 more
openaire   +3 more sources

Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer [PDF]

, 2012
Introduction The presence of circulating tumor cells (CTC) is an independent prognostic factor for progression-free survival and breast cancer-related death (BRD) for patients with metastatic breast cancer beginning a new line of systemic therapy.
Arjan GJ Tibbe, Bas Franken, Istvan Vermes, Job van der Palen, Leon WMM Terstappen, Marco R de Groot, Walter JB Mastboom   +6 more
core   +23 more sources

Human Leukocyte Antigen Class I Expression and Natural Killer Cell Infiltration and Its Correlation with Prognostic Features in Luminal Breast Cancers [PDF]

Breast Cancer: Targets and Therapy
Maria Vernet-Tomas,1,2 Ivonne Vazquez,1,3 Francesc Olivares,3 David Lopez,3 Jose Yelamos,2,4 Laura Comerma1– 3 1Breast Diseases Unit, Hospital Del Mar, Barcelona, Spain; 2Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM ...
Vernet-Tomas M, Vazquez I, Olivares F, Lopez D, Yelamos J, Comerma L   +5 more
doaj   +2 more sources

Breast Cancer Heterogeneity in Latin America: A Scoping Review of Clinical-Pathological Characteristics, Molecular Subtypes, and Survival. [PDF]

World J Surg
Breast cancer in Latin America (LATAM) exhibits distinct clinical‐pathological and molecular features, shaped by genetic diversity and healthcare disparities. This scoping review evaluates these characteristics, focusing on histopathological, molecular subtype and survival patterns and their implications for future research and public health ...
Aponte-Rueda ME, Gómez-González FM, Merck B.   +2 more
europepmc   +2 more sources

Programmed Death Ligand 1 (PDL1) Expression in Neoadjuvant Triple-Negative Breast Cancer: Association With Chemotherapy Response and Residual Cancer Burden. [PDF]

Breast J
Background Programmed death ligand 1 (PDL1) expression in tumors is linked to immune evasion in various cancers, making these patients potential candidates for PDL1 inhibitors. Although immune checkpoint blockade therapy has gained approval for breast cancer treatment, especially triple‐negative breast cancer (TNBC), there is a lack of PDL1 expression ...
Hashmi AA, Wahid N, Mudassir G, Irfan M, Malik UA, Khan EY, Abu Bakar SM, Faridi N.   +7 more
europepmc   +2 more sources

Evaluation of CD9 Expression of Tumour Cells and Stromal Immune Cells in Breast Carcinoma by Immunohistochemistry [PDF]

Journal of Clinical and Diagnostic Research, 2022
Introduction: Cluster of Differentiation 9 (CD9), known as Motility Related Protein (MRP-1) regulates cell adhesion, motility, migration and proliferation.
RV Sowjanya Lakshmi, ML Harendra Kumar, K Mohan Kumar   +2 more
doaj   +1 more source

[Neuroendocrine expression markers in triple-negative, luminal-A, luminal-B and HER2neu breast cancer]. [PDF]

Rev Med Inst Mex Seguro Soc
Primary breast tumors with neuroendocrine (NE) differentiation are a heterogeneous tumor group with diversity of biological behavior, with poorly defined prevalence and prognosis.To evaluate the chromogranin, synaptophysin, CD56, INSM1 markers expression prevalence and the association between NE differentiation and tumor molecular type.Observational ...
Barboza-García YG, Ramírez-Balderrama L, Murguía-Pérez M, Hernández-González MA, Landeros-Navarro IY.   +4 more
europepmc   +3 more sources

Predictive Value of Excision Repair Cross Complementation Group 1 (ERCC1) by Immunohistochemistry for Determining Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancers. [PDF]

Breast J
Introduction: Triple‐negative breast cancers (TNBCs) constitute a significant proportion of breast cancers in Pakistan. Owing to the lack of expression of hormone (estrogen/progesterone) receptor and human epidermal growth factor receptor 2 (HER2neu), treatment options for TNBCs are limited.
Hashmi AA, Ajaz Y, Sajjad M, Zia F, Irfan M, Abu Bakar SM, Khan EY, Faridi N.   +7 more
europepmc   +2 more sources

A clinical case of cardioprotective therapy with exogenous phosphocreatine during chemotherapy and anti HER2-neu therapy in a patient with breast cancer

Клинический разбор в общей медицине, 2023
The authors describe a clinical observation of cardiotoxicity of anticancer targeted therapy in a young patient with HER2neu-positive breast cancer. The results of instrumental examinations demonstrating manifestations of cardiotoxicity are presented ...
Andrey L. Pylev, Vyacheslav A. Lisovoy, Olga S. Kozlova   +2 more
doaj   +1 more source

Remission of Her2neu Amplified Breast Carcinoma Involving Brain and Leptomeninges with Concurrent Disappearance of Her2neu Amplified Circulating Tumor Cells Following Intrathecal and Systemic Delivery of Trastuzumab

Annals of Case Reports, 2023
exaly   +2 more sources